nodes	percent_of_prediction	percent_of_DWPC	metapath
Apixaban—ABCG2—Dactinomycin—testicular cancer	0.106	0.114	CbGbCtD
Apixaban—ABCG2—Carboplatin—testicular cancer	0.071	0.0769	CbGbCtD
Apixaban—CYP3A5—Ifosfamide—testicular cancer	0.0691	0.0748	CbGbCtD
Apixaban—CYP2C8—Ifosfamide—testicular cancer	0.0664	0.0719	CbGbCtD
Apixaban—ABCG2—Cisplatin—testicular cancer	0.0607	0.0657	CbGbCtD
Apixaban—ABCG2—Etoposide—testicular cancer	0.0596	0.0645	CbGbCtD
Apixaban—CYP2C19—Ifosfamide—testicular cancer	0.0557	0.0604	CbGbCtD
Apixaban—CYP2C9—Ifosfamide—testicular cancer	0.0463	0.0502	CbGbCtD
Apixaban—ABCG2—Doxorubicin—testicular cancer	0.0407	0.044	CbGbCtD
Apixaban—ABCG2—Methotrexate—testicular cancer	0.0394	0.0426	CbGbCtD
Apixaban—ABCB1—Dactinomycin—testicular cancer	0.0381	0.0412	CbGbCtD
Apixaban—CYP3A5—Etoposide—testicular cancer	0.033	0.0358	CbGbCtD
Apixaban—CYP2C8—Etoposide—testicular cancer	0.0318	0.0344	CbGbCtD
Apixaban—CYP3A4—Ifosfamide—testicular cancer	0.0269	0.0292	CbGbCtD
Apixaban—CYP1A2—Etoposide—testicular cancer	0.0246	0.0266	CbGbCtD
Apixaban—ABCB1—Vinblastine—testicular cancer	0.0239	0.0258	CbGbCtD
Apixaban—CYP2C9—Cisplatin—testicular cancer	0.0225	0.0244	CbGbCtD
Apixaban—ABCB1—Cisplatin—testicular cancer	0.0219	0.0237	CbGbCtD
Apixaban—ABCB1—Etoposide—testicular cancer	0.0215	0.0233	CbGbCtD
Apixaban—ABCB1—Doxorubicin—testicular cancer	0.0147	0.0159	CbGbCtD
Apixaban—CYP3A4—Vinblastine—testicular cancer	0.0143	0.0155	CbGbCtD
Apixaban—ABCB1—Methotrexate—testicular cancer	0.0142	0.0154	CbGbCtD
Apixaban—CYP3A4—Etoposide—testicular cancer	0.0129	0.0139	CbGbCtD
Apixaban—CYP3A4—Doxorubicin—testicular cancer	0.00878	0.00951	CbGbCtD
Apixaban—Rectal haemorrhage—Vinblastine—testicular cancer	0.00148	0.0193	CcSEcCtD
Apixaban—Haematemesis—Ifosfamide—testicular cancer	0.00138	0.0181	CcSEcCtD
Apixaban—Petechiae—Ifosfamide—testicular cancer	0.00117	0.0153	CcSEcCtD
Apixaban—Haematochezia—Epirubicin—testicular cancer	0.00106	0.0138	CcSEcCtD
Apixaban—Drug hypersensitivity—Epirubicin—testicular cancer	0.00106	0.0138	CcSEcCtD
Apixaban—Drug hypersensitivity—Doxorubicin—testicular cancer	0.000978	0.0128	CcSEcCtD
Apixaban—Haematochezia—Doxorubicin—testicular cancer	0.000978	0.0128	CcSEcCtD
Apixaban—Gingival bleeding—Epirubicin—testicular cancer	0.000751	0.0098	CcSEcCtD
Apixaban—Liver function test abnormal—Dactinomycin—testicular cancer	0.000704	0.00919	CcSEcCtD
Apixaban—Transaminases increased—Epirubicin—testicular cancer	0.0007	0.00914	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Ifosfamide—testicular cancer	0.000698	0.00912	CcSEcCtD
Apixaban—Gingival bleeding—Doxorubicin—testicular cancer	0.000694	0.00907	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Dactinomycin—testicular cancer	0.000686	0.00896	CcSEcCtD
Apixaban—Haemoglobin—Vinblastine—testicular cancer	0.000673	0.00879	CcSEcCtD
Apixaban—Haemorrhage—Vinblastine—testicular cancer	0.000669	0.00874	CcSEcCtD
Apixaban—Haematemesis—Methotrexate—testicular cancer	0.000655	0.00856	CcSEcCtD
Apixaban—Transaminases increased—Doxorubicin—testicular cancer	0.000648	0.00846	CcSEcCtD
Apixaban—Blood alkaline phosphatase increased—Etoposide—testicular cancer	0.000634	0.00828	CcSEcCtD
Apixaban—Breast disorder—Ifosfamide—testicular cancer	0.000631	0.00824	CcSEcCtD
Apixaban—Haematemesis—Epirubicin—testicular cancer	0.000613	0.00801	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Cisplatin—testicular cancer	0.000602	0.00786	CcSEcCtD
Apixaban—Haematuria—Bleomycin—testicular cancer	0.0006	0.00784	CcSEcCtD
Apixaban—Anaemia—Chlorambucil—testicular cancer	0.000588	0.00768	CcSEcCtD
Apixaban—Vaginal haemorrhage—Epirubicin—testicular cancer	0.000575	0.00752	CcSEcCtD
Apixaban—Haemoptysis—Epirubicin—testicular cancer	0.000575	0.00752	CcSEcCtD
Apixaban—Haemoglobin—Bleomycin—testicular cancer	0.000568	0.00742	CcSEcCtD
Apixaban—Haematemesis—Doxorubicin—testicular cancer	0.000567	0.00741	CcSEcCtD
Apixaban—Haemorrhage—Bleomycin—testicular cancer	0.000565	0.00738	CcSEcCtD
Apixaban—Petechiae—Methotrexate—testicular cancer	0.000553	0.00723	CcSEcCtD
Apixaban—Breast disorder—Cisplatin—testicular cancer	0.000544	0.00711	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Cisplatin—testicular cancer	0.000542	0.00708	CcSEcCtD
Apixaban—Anaemia—Vinblastine—testicular cancer	0.000539	0.00703	CcSEcCtD
Apixaban—Haemoptysis—Doxorubicin—testicular cancer	0.000532	0.00695	CcSEcCtD
Apixaban—Vaginal haemorrhage—Doxorubicin—testicular cancer	0.000532	0.00695	CcSEcCtD
Apixaban—Petechiae—Epirubicin—testicular cancer	0.000518	0.00676	CcSEcCtD
Apixaban—Haematuria—Ifosfamide—testicular cancer	0.000513	0.0067	CcSEcCtD
Apixaban—Hepatobiliary disease—Ifosfamide—testicular cancer	0.000509	0.00665	CcSEcCtD
Apixaban—Thrombocytopenia—Chlorambucil—testicular cancer	0.000508	0.00664	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Etoposide—testicular cancer	0.000486	0.00635	CcSEcCtD
Apixaban—Haemoglobin—Ifosfamide—testicular cancer	0.000486	0.00634	CcSEcCtD
Apixaban—Haemorrhage—Ifosfamide—testicular cancer	0.000483	0.00631	CcSEcCtD
Apixaban—Petechiae—Doxorubicin—testicular cancer	0.000479	0.00626	CcSEcCtD
Apixaban—Urinary tract disorder—Ifosfamide—testicular cancer	0.000477	0.00623	CcSEcCtD
Apixaban—Connective tissue disorder—Ifosfamide—testicular cancer	0.000475	0.0062	CcSEcCtD
Apixaban—Urethral disorder—Ifosfamide—testicular cancer	0.000474	0.00619	CcSEcCtD
Apixaban—Rectal haemorrhage—Epirubicin—testicular cancer	0.000472	0.00616	CcSEcCtD
Apixaban—Thrombocytopenia—Vinblastine—testicular cancer	0.000466	0.00608	CcSEcCtD
Apixaban—Anaemia—Bleomycin—testicular cancer	0.000455	0.00594	CcSEcCtD
Apixaban—Eye disorder—Ifosfamide—testicular cancer	0.000451	0.0059	CcSEcCtD
Apixaban—Blood bilirubin increased—Epirubicin—testicular cancer	0.00045	0.00588	CcSEcCtD
Apixaban—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.000448	0.00585	CcSEcCtD
Apixaban—Melaena—Methotrexate—testicular cancer	0.000445	0.00581	CcSEcCtD
Apixaban—Hepatobiliary disease—Cisplatin—testicular cancer	0.000439	0.00573	CcSEcCtD
Apixaban—Angiopathy—Ifosfamide—testicular cancer	0.000438	0.00572	CcSEcCtD
Apixaban—Immune system disorder—Ifosfamide—testicular cancer	0.000436	0.0057	CcSEcCtD
Apixaban—Rectal haemorrhage—Doxorubicin—testicular cancer	0.000436	0.0057	CcSEcCtD
Apixaban—Mediastinal disorder—Ifosfamide—testicular cancer	0.000435	0.00569	CcSEcCtD
Apixaban—Anaemia—Dactinomycin—testicular cancer	0.000424	0.00554	CcSEcCtD
Apixaban—Blood bilirubin increased—Doxorubicin—testicular cancer	0.000417	0.00544	CcSEcCtD
Apixaban—Melaena—Epirubicin—testicular cancer	0.000416	0.00543	CcSEcCtD
Apixaban—Ecchymosis—Methotrexate—testicular cancer	0.000411	0.00537	CcSEcCtD
Apixaban—Urinary tract disorder—Cisplatin—testicular cancer	0.000411	0.00537	CcSEcCtD
Apixaban—Connective tissue disorder—Cisplatin—testicular cancer	0.000409	0.00535	CcSEcCtD
Apixaban—Urethral disorder—Cisplatin—testicular cancer	0.000408	0.00533	CcSEcCtD
Apixaban—Hepatobiliary disease—Etoposide—testicular cancer	0.000402	0.00525	CcSEcCtD
Apixaban—Anaphylactic shock—Bleomycin—testicular cancer	0.000402	0.00525	CcSEcCtD
Apixaban—Thrombocytopenia—Bleomycin—testicular cancer	0.000393	0.00514	CcSEcCtD
Apixaban—Eye disorder—Cisplatin—testicular cancer	0.000389	0.00508	CcSEcCtD
Apixaban—Anaemia—Ifosfamide—testicular cancer	0.000389	0.00508	CcSEcCtD
Apixaban—Ecchymosis—Epirubicin—testicular cancer	0.000385	0.00503	CcSEcCtD
Apixaban—Melaena—Doxorubicin—testicular cancer	0.000385	0.00503	CcSEcCtD
Apixaban—Hypersensitivity—Chlorambucil—testicular cancer	0.000382	0.00499	CcSEcCtD
Apixaban—Diabetes mellitus—Methotrexate—testicular cancer	0.00038	0.00496	CcSEcCtD
Apixaban—Urinary tract disorder—Etoposide—testicular cancer	0.000377	0.00492	CcSEcCtD
Apixaban—Immune system disorder—Cisplatin—testicular cancer	0.000376	0.00491	CcSEcCtD
Apixaban—Mediastinal disorder—Cisplatin—testicular cancer	0.000375	0.0049	CcSEcCtD
Apixaban—Hypotension—Bleomycin—testicular cancer	0.000375	0.0049	CcSEcCtD
Apixaban—Urethral disorder—Etoposide—testicular cancer	0.000374	0.00489	CcSEcCtD
Apixaban—Thrombocytopenia—Dactinomycin—testicular cancer	0.000367	0.00479	CcSEcCtD
Apixaban—Eye disorder—Etoposide—testicular cancer	0.000357	0.00466	CcSEcCtD
Apixaban—Ecchymosis—Doxorubicin—testicular cancer	0.000356	0.00465	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000356	0.00464	CcSEcCtD
Apixaban—Blood alkaline phosphatase increased—Epirubicin—testicular cancer	0.000355	0.00464	CcSEcCtD
Apixaban—Diabetes mellitus—Epirubicin—testicular cancer	0.000355	0.00464	CcSEcCtD
Apixaban—Hypersensitivity—Vinblastine—testicular cancer	0.00035	0.00458	CcSEcCtD
Apixaban—Angiopathy—Etoposide—testicular cancer	0.000346	0.00452	CcSEcCtD
Apixaban—Immune system disorder—Etoposide—testicular cancer	0.000345	0.0045	CcSEcCtD
Apixaban—Mediastinal disorder—Etoposide—testicular cancer	0.000344	0.00449	CcSEcCtD
Apixaban—Anaphylactic shock—Ifosfamide—testicular cancer	0.000343	0.00448	CcSEcCtD
Apixaban—Nervous system disorder—Ifosfamide—testicular cancer	0.000337	0.0044	CcSEcCtD
Apixaban—Thrombocytopenia—Ifosfamide—testicular cancer	0.000336	0.00439	CcSEcCtD
Apixaban—Anaemia—Cisplatin—testicular cancer	0.000335	0.00438	CcSEcCtD
Apixaban—Skin disorder—Ifosfamide—testicular cancer	0.000333	0.00435	CcSEcCtD
Apixaban—Blood alkaline phosphatase increased—Doxorubicin—testicular cancer	0.000329	0.0043	CcSEcCtD
Apixaban—Diabetes mellitus—Doxorubicin—testicular cancer	0.000329	0.0043	CcSEcCtD
Apixaban—Hypotension—Ifosfamide—testicular cancer	0.000321	0.00419	CcSEcCtD
Apixaban—Dizziness—Vinblastine—testicular cancer	0.000314	0.00411	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Epirubicin—testicular cancer	0.000309	0.00404	CcSEcCtD
Apixaban—Nausea—Chlorambucil—testicular cancer	0.000308	0.00403	CcSEcCtD
Apixaban—Anaemia—Etoposide—testicular cancer	0.000307	0.00401	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000307	0.004	CcSEcCtD
Apixaban—Liver function test abnormal—Methotrexate—testicular cancer	0.000305	0.00398	CcSEcCtD
Apixaban—Breast disorder—Methotrexate—testicular cancer	0.000299	0.0039	CcSEcCtD
Apixaban—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000296	0.00387	CcSEcCtD
Apixaban—Anaphylactic shock—Cisplatin—testicular cancer	0.000296	0.00386	CcSEcCtD
Apixaban—Hypersensitivity—Bleomycin—testicular cancer	0.000296	0.00386	CcSEcCtD
Apixaban—Loss of consciousness—Etoposide—testicular cancer	0.000292	0.00381	CcSEcCtD
Apixaban—Nervous system disorder—Cisplatin—testicular cancer	0.00029	0.00379	CcSEcCtD
Apixaban—Thrombocytopenia—Cisplatin—testicular cancer	0.00029	0.00378	CcSEcCtD
Apixaban—Skin disorder—Cisplatin—testicular cancer	0.000287	0.00375	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	0.000286	0.00374	CcSEcCtD
Apixaban—Liver function test abnormal—Epirubicin—testicular cancer	0.000285	0.00373	CcSEcCtD
Apixaban—Nausea—Vinblastine—testicular cancer	0.000282	0.00369	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000281	0.00367	CcSEcCtD
Apixaban—Breast disorder—Epirubicin—testicular cancer	0.000279	0.00365	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000278	0.00364	CcSEcCtD
Apixaban—Hypotension—Cisplatin—testicular cancer	0.000276	0.00361	CcSEcCtD
Apixaban—Hypersensitivity—Dactinomycin—testicular cancer	0.000276	0.0036	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000273	0.00356	CcSEcCtD
Apixaban—Anaphylactic shock—Etoposide—testicular cancer	0.000271	0.00354	CcSEcCtD
Apixaban—Thrombocytopenia—Etoposide—testicular cancer	0.000265	0.00347	CcSEcCtD
Apixaban—Liver function test abnormal—Doxorubicin—testicular cancer	0.000264	0.00345	CcSEcCtD
Apixaban—Skin disorder—Etoposide—testicular cancer	0.000263	0.00344	CcSEcCtD
Apixaban—Breast disorder—Doxorubicin—testicular cancer	0.000259	0.00338	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000258	0.00336	CcSEcCtD
Apixaban—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000255	0.00334	CcSEcCtD
Apixaban—Hypotension—Etoposide—testicular cancer	0.000253	0.00331	CcSEcCtD
Apixaban—Rash—Bleomycin—testicular cancer	0.000253	0.00331	CcSEcCtD
Apixaban—Dermatitis—Bleomycin—testicular cancer	0.000253	0.0033	CcSEcCtD
Apixaban—Hypersensitivity—Ifosfamide—testicular cancer	0.000253	0.0033	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000252	0.0033	CcSEcCtD
Apixaban—Haematuria—Methotrexate—testicular cancer	0.000243	0.00317	CcSEcCtD
Apixaban—Hepatobiliary disease—Methotrexate—testicular cancer	0.000241	0.00314	CcSEcCtD
Apixaban—Epistaxis—Methotrexate—testicular cancer	0.00024	0.00314	CcSEcCtD
Apixaban—Nausea—Bleomycin—testicular cancer	0.000239	0.00312	CcSEcCtD
Apixaban—Rash—Dactinomycin—testicular cancer	0.000236	0.00308	CcSEcCtD
Apixaban—Gastrointestinal disorder—Etoposide—testicular cancer	0.000234	0.00306	CcSEcCtD
Apixaban—Haemoglobin—Methotrexate—testicular cancer	0.00023	0.003	CcSEcCtD
Apixaban—Haemorrhage—Methotrexate—testicular cancer	0.000229	0.00299	CcSEcCtD
Apixaban—Haematuria—Epirubicin—testicular cancer	0.000227	0.00297	CcSEcCtD
Apixaban—Dizziness—Ifosfamide—testicular cancer	0.000227	0.00296	CcSEcCtD
Apixaban—Urinary tract disorder—Methotrexate—testicular cancer	0.000226	0.00295	CcSEcCtD
Apixaban—Hepatobiliary disease—Epirubicin—testicular cancer	0.000225	0.00294	CcSEcCtD
Apixaban—Epistaxis—Epirubicin—testicular cancer	0.000225	0.00294	CcSEcCtD
Apixaban—Urethral disorder—Methotrexate—testicular cancer	0.000224	0.00293	CcSEcCtD
Apixaban—Nausea—Dactinomycin—testicular cancer	0.000222	0.00291	CcSEcCtD
Apixaban—Hypersensitivity—Cisplatin—testicular cancer	0.000218	0.00285	CcSEcCtD
Apixaban—Rash—Ifosfamide—testicular cancer	0.000216	0.00283	CcSEcCtD
Apixaban—Dermatitis—Ifosfamide—testicular cancer	0.000216	0.00282	CcSEcCtD
Apixaban—Haemoglobin—Epirubicin—testicular cancer	0.000215	0.00281	CcSEcCtD
Apixaban—Haemorrhage—Epirubicin—testicular cancer	0.000214	0.00279	CcSEcCtD
Apixaban—Eye disorder—Methotrexate—testicular cancer	0.000214	0.00279	CcSEcCtD
Apixaban—Urinary tract disorder—Epirubicin—testicular cancer	0.000211	0.00276	CcSEcCtD
Apixaban—Haematuria—Doxorubicin—testicular cancer	0.00021	0.00275	CcSEcCtD
Apixaban—Connective tissue disorder—Epirubicin—testicular cancer	0.00021	0.00275	CcSEcCtD
Apixaban—Urethral disorder—Epirubicin—testicular cancer	0.00021	0.00274	CcSEcCtD
Apixaban—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000208	0.00272	CcSEcCtD
Apixaban—Epistaxis—Doxorubicin—testicular cancer	0.000208	0.00272	CcSEcCtD
Apixaban—Angiopathy—Methotrexate—testicular cancer	0.000207	0.00271	CcSEcCtD
Apixaban—Immune system disorder—Methotrexate—testicular cancer	0.000206	0.0027	CcSEcCtD
Apixaban—Mediastinal disorder—Methotrexate—testicular cancer	0.000206	0.00269	CcSEcCtD
Apixaban—Nausea—Ifosfamide—testicular cancer	0.000204	0.00266	CcSEcCtD
Apixaban—Eye disorder—Epirubicin—testicular cancer	0.0002	0.00261	CcSEcCtD
Apixaban—Hypersensitivity—Etoposide—testicular cancer	0.0002	0.00261	CcSEcCtD
Apixaban—Haemoglobin—Doxorubicin—testicular cancer	0.000199	0.0026	CcSEcCtD
Apixaban—Haemorrhage—Doxorubicin—testicular cancer	0.000198	0.00258	CcSEcCtD
Apixaban—Urinary tract disorder—Doxorubicin—testicular cancer	0.000195	0.00255	CcSEcCtD
Apixaban—Connective tissue disorder—Doxorubicin—testicular cancer	0.000194	0.00254	CcSEcCtD
Apixaban—Angiopathy—Epirubicin—testicular cancer	0.000194	0.00253	CcSEcCtD
Apixaban—Urethral disorder—Doxorubicin—testicular cancer	0.000194	0.00253	CcSEcCtD
Apixaban—Immune system disorder—Epirubicin—testicular cancer	0.000193	0.00252	CcSEcCtD
Apixaban—Mediastinal disorder—Epirubicin—testicular cancer	0.000193	0.00252	CcSEcCtD
Apixaban—Rash—Cisplatin—testicular cancer	0.000187	0.00244	CcSEcCtD
Apixaban—Dermatitis—Cisplatin—testicular cancer	0.000186	0.00243	CcSEcCtD
Apixaban—Eye disorder—Doxorubicin—testicular cancer	0.000185	0.00242	CcSEcCtD
Apixaban—Anaemia—Methotrexate—testicular cancer	0.000184	0.0024	CcSEcCtD
Apixaban—Angiopathy—Doxorubicin—testicular cancer	0.00018	0.00235	CcSEcCtD
Apixaban—Dizziness—Etoposide—testicular cancer	0.000179	0.00234	CcSEcCtD
Apixaban—Immune system disorder—Doxorubicin—testicular cancer	0.000179	0.00233	CcSEcCtD
Apixaban—Mediastinal disorder—Doxorubicin—testicular cancer	0.000178	0.00233	CcSEcCtD
Apixaban—Nausea—Cisplatin—testicular cancer	0.000176	0.0023	CcSEcCtD
Apixaban—Anaemia—Epirubicin—testicular cancer	0.000172	0.00225	CcSEcCtD
Apixaban—Rash—Etoposide—testicular cancer	0.000171	0.00223	CcSEcCtD
Apixaban—Dermatitis—Etoposide—testicular cancer	0.000171	0.00223	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000168	0.0022	CcSEcCtD
Apixaban—Syncope—Epirubicin—testicular cancer	0.000167	0.00218	CcSEcCtD
Apixaban—Loss of consciousness—Epirubicin—testicular cancer	0.000164	0.00214	CcSEcCtD
Apixaban—Anaphylactic shock—Methotrexate—testicular cancer	0.000162	0.00212	CcSEcCtD
Apixaban—Nausea—Etoposide—testicular cancer	0.000161	0.0021	CcSEcCtD
Apixaban—Nervous system disorder—Methotrexate—testicular cancer	0.000159	0.00208	CcSEcCtD
Apixaban—Anaemia—Doxorubicin—testicular cancer	0.000159	0.00208	CcSEcCtD
Apixaban—Thrombocytopenia—Methotrexate—testicular cancer	0.000159	0.00208	CcSEcCtD
Apixaban—Skin disorder—Methotrexate—testicular cancer	0.000158	0.00206	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000157	0.00206	CcSEcCtD
Apixaban—Syncope—Doxorubicin—testicular cancer	0.000154	0.00202	CcSEcCtD
Apixaban—Anaphylactic shock—Epirubicin—testicular cancer	0.000152	0.00198	CcSEcCtD
Apixaban—Hypotension—Methotrexate—testicular cancer	0.000152	0.00198	CcSEcCtD
Apixaban—Loss of consciousness—Doxorubicin—testicular cancer	0.000151	0.00198	CcSEcCtD
Apixaban—Shock—Epirubicin—testicular cancer	0.000149	0.00195	CcSEcCtD
Apixaban—Nervous system disorder—Epirubicin—testicular cancer	0.000149	0.00195	CcSEcCtD
Apixaban—Thrombocytopenia—Epirubicin—testicular cancer	0.000149	0.00194	CcSEcCtD
Apixaban—Skin disorder—Epirubicin—testicular cancer	0.000148	0.00193	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000146	0.0019	CcSEcCtD
Apixaban—Hypotension—Epirubicin—testicular cancer	0.000142	0.00185	CcSEcCtD
Apixaban—Anaphylactic shock—Doxorubicin—testicular cancer	0.000141	0.00184	CcSEcCtD
Apixaban—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00014	0.00183	CcSEcCtD
Apixaban—Shock—Doxorubicin—testicular cancer	0.000138	0.00181	CcSEcCtD
Apixaban—Nervous system disorder—Doxorubicin—testicular cancer	0.000138	0.0018	CcSEcCtD
Apixaban—Thrombocytopenia—Doxorubicin—testicular cancer	0.000138	0.0018	CcSEcCtD
Apixaban—Skin disorder—Doxorubicin—testicular cancer	0.000137	0.00178	CcSEcCtD
Apixaban—Hypotension—Doxorubicin—testicular cancer	0.000131	0.00172	CcSEcCtD
Apixaban—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000131	0.00171	CcSEcCtD
Apixaban—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000121	0.00159	CcSEcCtD
Apixaban—Hypersensitivity—Methotrexate—testicular cancer	0.00012	0.00156	CcSEcCtD
Apixaban—Hypersensitivity—Epirubicin—testicular cancer	0.000112	0.00146	CcSEcCtD
Apixaban—Dizziness—Methotrexate—testicular cancer	0.000107	0.0014	CcSEcCtD
Apixaban—Hypersensitivity—Doxorubicin—testicular cancer	0.000104	0.00135	CcSEcCtD
Apixaban—Rash—Methotrexate—testicular cancer	0.000102	0.00134	CcSEcCtD
Apixaban—Dermatitis—Methotrexate—testicular cancer	0.000102	0.00134	CcSEcCtD
Apixaban—Dizziness—Epirubicin—testicular cancer	0.0001	0.00131	CcSEcCtD
Apixaban—Nausea—Methotrexate—testicular cancer	9.64e-05	0.00126	CcSEcCtD
Apixaban—Rash—Epirubicin—testicular cancer	9.58e-05	0.00125	CcSEcCtD
Apixaban—Dermatitis—Epirubicin—testicular cancer	9.57e-05	0.00125	CcSEcCtD
Apixaban—Dizziness—Doxorubicin—testicular cancer	9.3e-05	0.00121	CcSEcCtD
Apixaban—Nausea—Epirubicin—testicular cancer	9.03e-05	0.00118	CcSEcCtD
Apixaban—Rash—Doxorubicin—testicular cancer	8.87e-05	0.00116	CcSEcCtD
Apixaban—Dermatitis—Doxorubicin—testicular cancer	8.86e-05	0.00116	CcSEcCtD
Apixaban—Nausea—Doxorubicin—testicular cancer	8.35e-05	0.00109	CcSEcCtD
